The aim of this study was to retrospectively assess the recanalization rate, factors associated with and time taken for recanalization to occur in a matched ruptured and unruptured aneurysm population that were treated with endovascular coiling. Ruptured and unruptured aneurysms treated between 2002 and 2007 were matched for aneurysm location, diameter and neck size. Recanalization rate, time to recanalize, re-treatment rate and clinical outcome were analysed. Ninety-eight matched ruptured and unruptured aneurysms (49 aneurysms in each group) were studied. 46.8% of aneurysms in the ruptured group achieved complete obliteration on the initial post treatment angiogram versus 34.7% in the unruptured group. The ruptured group had a higher rate of recanalization (40.4% versus 20.4%). 25.5% of aneurysms had significant recanalization in the ruptured group versus 6.1% in the unruptured group (p=0.009). The retreatment rate was higher in the ruptured group (21.3% versus 6%). Ruptured aneurysms took a shorter time to recanalize with a mean time of 5.3±3.8 months versus 12.4±7.7months (p=0.003). Multivariate logistic regression analysis found neck size (p=0.0098), wide neck morphology (p=0.0174), aneurysm diameter (p< 0.0001) and ruptured aneurysms (p=0.0372) were significant predictors of recanalization. The majority of patients in both groups had a good outcome with GOS=5 (85.7% and 83.7%) but two deaths occurred in the ruptured group. Ruptured and unruptured aneurysms showed significant differences in rate, degree and timing of recanalization, thus requiring different protocols for imaging follow-up post endovascular treatment. Earlier and more frequent imaging follow-up is recommended for ruptured aneurysms.

CTA is adequate for detecting central vasospasm in symptomatic SAH patients. A negative result should not prevent further investigation especially when evaluating arterial segments adjacent to metal artefacts from coils or clips. CTA is helpful in treatment decision making specifically regarding the need for balloon angioplasty.

No abstract

Introduction:The recent DAWN trial created a paradigm shift in acute stroke treatment from 'time-based' criteria (within 6 hours) to 'tissue-based' criteria dependent on advanced neuroimaging such as CT perfusion (CTP). This has expanded the thrombectomy window from 6 to 24 hours and has major implications for healthcare providers involved in acute stroke management. Our aim is to characterise changes in the utilisation, diagnostic yield and accuracy of CTP in the diagnosis of acute stroke in the year following the DAWN trial. Methods: Four hundred and forty-three patients underwent CTP for investigation of suspected stroke between 1 January 2017 and 31 December 2018. Studies in 2017 were considered 'pre-DAWN' while studies in 2018 were considered 'post-DAWN trial'. Electronic medical records were reviewed to extract patient characteristics. Each patient was categorised as early presenter (within 6 hours) or late presenter (over 6 hours). Chi-squared tests were performed to assess for differences in proportions between the 2 years. Results: There was a 50% increase in CTP performed from 177 in 2017 to 266 in 2018. The proportion of all CT that were CTP increased by 40% while CTP in late presenters increased by 70% in 2018. The sensitivity, specificity and proportions of CTP with a final diagnosis of acute stroke, TIA or nonstroke did not demonstrate statistically significant differences between the 2 years. Conclusions: The CTP utilisation, particularly in late presenters, has substantially increased since the DAWN trial. This contributes to increasing burden on healthcare services related to the diagnosis and management of stroke.